Ferring Pharmaceutical Opens Gene Therapy Manufacturing Facility in Parsippany

Ferring Pharmaceutical inaugurated a 12,000-square-foot facility in Parsippany to manufacture ADSTILADRIN, the first FDA-approved gene therapy for high-risk bladder cancer. Delivered via catheter every three months, the therapy targets patients who do not respond to Bacillus Calmette-Guérin. Senior VP Bipin Dalmia stated that the objective is to treat bladder cancer as a chronic disease, allowing cancer-free patients to continue therapy for up to five years. Ferring has invested over $1 billion in ADSTILADRIN's development, including almost $500 million in manufacturing infrastructure. The Parsippany site will serve as the global hub for the final dosage form, while the drug substance will be produced in Finland.

Currently, the facility employs 23 individuals, with plans to expand to 67. Regulatory submissions for ADSTILADRIN are in progress in the European Union, Canada, and Israel, with additional countries expected to follow. This marks a significant advancement in gene therapy manufacturing, with potential for future product expansion at the site.